Sign in
Taking people in South KoreaPhase 4

Comparing two blood-thinning plans after imaging-guided heart stent placement

Tests a tailored blood-thinning plan against conventional care in adults with coronary artery disease.

Key facts

Who runs it
Asan Medical Center
Where
Bucheon-si, Busan, Changwon, Chuncheon, Chungju, Daegu, Daejeon, Gangneung, Hwaseong-si, Ilsan, Jeju City, Jeonju, Jinju, Jungnam, Seoul, Suwon, Uijeongbu-si, Ulsan, and Yangsan, South KoreaSee the 33 sites
Trial code
Registry title
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
Status
Recruiting
Phase
Phase 4
People taking part
3,944 people, planned
Started
21 Oct 2022
Expected to end
31 Dec 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • aspirin
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with coronary artery disease who got a drug-eluting stent that was placed and checked with IVUS or OCT imaging. It compares two ways of using blood-thinning pills afterwards.

Age
19 years or older
Sex
Men and women can join.
Disease stage
New (de novo) narrowing of a heart artery that needs a drug-eluting stent. The stent must have been placed well, as checked by IVUS or OCT imaging.
Earlier treatment
Must have had a stent placed with IVUS or OCT guidance and judged well placed. Cannot need long-term oral anticoagulants or cilostazol.

Main reasons for not taking part

  • Bypass graft lesions or in-stent restenosis
  • Platelet count below 80,000/μl, or active bleeding or very high bleeding risk
  • Bleeding in the brain, or a stroke or TIA in the past 6 months
  • Needs long-term oral anticoagulants or cilostazol
  • Cancer in the past 3 years, pregnancy or breast-feeding, or cardiogenic shock

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Men or women ≥19 years
  • Typical chest pain or objective evidence of myocardial ischemia suitable for PCI
  • Significant de novo coronary artery lesions suitable for DES implantation
  • Patients who underwent optimized stent implantation either by IVUS or OCT; Using IVUS; MSA >5.5 mm2, or MSA >90% of the MLA at the distal reference segment; Plaque burden <50% with 5 mm of both stent edge; No edge dissection; thrombus or plaque protrusion occupying < 10% of the stent area; Using OCT; MSA >4.5 mm2, or MSA >90% of the MLA at the distal reference segment; No significant malapposition; No significant edge dissection†; thrombus or plaque protrusion occupying < 10% of the stent area; (*Significant malapposition is defined as strut separation ≥ 0.3 mm from the vessel wall extending over a length > 3 mm; †Significant dissection is defined as a dissection penetrating the medial layer and extending over more than one quadrant.)
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site

Who cannot take part

  • Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP antagonist is planned within 12 months after the procedure
  • Hypersensitivity or contraindication to device material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated
  • Any history of hemorrhagic stroke or intracranial hemorrhage / TIA or ischemic stroke within the past 6 months
  • A known intolerance or hypersensitivity to a study drug (aspirin, clopidogrel or ticagrelor) or heparin
  • A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer
  • History of liver cirrhosis (Child-Pugh B or C) or biliary tract obstruction
  • Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a high risk for bleeding, malignancies with a high risk for bleeding)
  • Persistent thrombocytopenia (platelet count <80,000/μl)
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study
  • Life expectancy < 1 years for any non-cardiac or cardiac causes
  • Angiographic exclusion criteria: any of the followings 1. Bypass graft lesions 2. Lesions in which impaired delivery of imaging catheters is expected:; Extreme angulation (≥90°) proximal to or within the target lesion; Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion; Heavy calcification proximal to or within the target lesion
  • In-stent restenosis
  • Patients requiring long-term oral anticoagulants or cilostazol
  • Cardiogenic shock at the index admission
  • Patient's pregnant or breast-feeding
  • Unwillingness or inability to comply with the procedures described in this protocol

Where in South Korea

  • Bucheon Sejong HospitalBucheon-si, South KoreaContact: Ha Wook Park, MDTaking people
  • Dong-A University HospitalBusan, South KoreaContact: Yong Rak Cho, MDTaking people
  • Inje University Busan Paik HospitalBusan, South KoreaContact: Tae Hyun Yang, MDNot yet recruiting
  • Inje University Haeundae Paik HospitalBusan, South KoreaContact: Dongk-kie Kim, MDNot yet recruiting
  • Kosin University Gospel HospitalBusan, South KoreaContact: Jeong Ho Heo, MDTaking people
  • Gyeongsang National University Changwon hospitalChangwon, South KoreaContact: Jae Seok Bae, MDTaking people
  • Kangwon National University HospitalChuncheon, South KoreaContact: Bong Ki Lee, MDTaking people
  • Chungbuk National University HospitalChungju, South KoreaContact: Sang Min Kim, MDTaking people
  • Daegu Catholic Univ. Medical CenterDaegu, South KoreaContact: Jin Bae Lee, MDNot yet recruiting
  • Keimyung University - Dongsan Medical CenterDaegu, South KoreaContact: Hyuck jun yoon, MDTaking people
  • Kyungpook National University HospitalDaegu, South KoreaContact: NAM KYUN KIM, MDTaking people
  • Veterans HospitalDaegu, South KoreaContact: Sang Wook Kang, MDTaking people
  • The Catholic University of Korea, Daejeon ST.Mary's HospitalDaejeon, South KoreaContact: Kyusup Lee, MDTaking people
  • Gangneung Asan HospitalGangneung, South KoreaContact: Han Bit Park, MDTaking people
  • Hallym Univ. Medical Center.Hwaseong-si, South KoreaContact: Jeen Hwa Lee, MDNot yet recruiting
  • dongguk University Medical CenterIlsan, South KoreaContact: Jae sik Jang, MDNot yet recruiting
  • Jeju National University HospitalJeju City, South KoreaContact: Joon Hyouk Choi, MDTaking people
  • jeonbuk National University HospitalJeonju, South KoreaContact: Yisik Kim, MDTaking people
  • Gyeongsang National University HospitalJinju, South KoreaContact: Jin Sin Koh, MDTaking people
  • Chungnam National University HospitalJungnam, South KoreaContact: Jae Hwan Lee, MDTaking people
  • Chungnam National University Sejong HospitalJungnam, South KoreaContact: Won mook Hwang, MDTaking people
  • Dankook University HospitalJungnam, South KoreaContact: tae soo kang, MDTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Seung-Whan Lee, MDTaking people
  • Kangbuk Samsung HospitalSeoul, South KoreaContact: seung jae Lee, MDTaking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Soon Jun Hong, MDTaking people
  • The Catholic University of Korea, Eunpyeong St. Mary's HospitalSeoul, South KoreaContact: Pum Joon Kim, MDTaking people
  • Veterans Hospital Service Medical CenterSeoul, South KoreaContact: Chang Hoon Lee, MDTaking people
  • Ajou University HospitalSuwon, South KoreaContact: Myeong Ho Yoon, MDTaking people
  • The Catholic University of Korea St. Vincent's HospitalSuwon, South KoreaContact: Ji Sue Hong, RNNo longer taking part
  • The Catholic University of Korea Uijeongbu St. Mary's HospitalUijeongbu-si, South KoreaContact: Chan Joon Kim, MDNot yet recruiting
  • Dongkang HospitalUlsan, South KoreaContact: Byung jun Kim, MDNot yet recruiting
  • Ulsan University HospitalUlsan, South KoreaContact: Gyung Min Park, MDTaking people
  • Pusan National University Yangsan HospitalYangsan, South KoreaContact: Kook Jin Chun, MDNot yet recruiting

About the trial

What the trial wants to find out

Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)

Read full original descriptionShow less

Hypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS/OCT could act as an essential criterion for decision making for tailored antithrombotic strategy)

The 2 groups in the trial

  • Conventional ArmExisting treatment, for comparison

    The intended regimen is 12 months of DAPT with aspirin plus clopidogrel for CCS or aspirin plus a potent P2Y12 inhibitor (ticagrelor or prasugrel) for ACS. For patients with CCS, a minimum DAPT duration of 6 months is permitted at the treating physician's discretion.

    Treatment: aspirin

  • Tailored ArmTreatment being tested

    Patients with CCS receive 1 month of DAPT with aspirin plus clopidogrel, followed by 11 months of clopidogrel monotherapy. Patients with ACS receive 3 months of DAPT with aspirin plus a potent P2Y12 inhibitor (ticagrelor or prasugrel), followed by 9 months of potent P2Y12 inhibitor monotherapy.

    Treatment: aspirin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
Plain-language title
Comparing two blood-thinning plans after imaging-guided heart stent placementGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 September 2026